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Question {#ccr3523-sec-0001}
========

A 45‐year‐old female patient, who had breast cancer with metastases in the liver and lung, and treated with bevacizumab and docetaxel 5 months ago, reported the passage of flatus and stool through the vagina for about 2 months now. Apart from the breast cancer, her medical history was free and no reference to irradiation or other inflammatory condition in gastrointestinal tract (according to colonoscopy which was done at the time of diagnosis of breast cancer) was mentioned.

Diagnosis {#ccr3523-sec-0002}
=========

A rectovaginal fistula {#ccr3523-sec-0003}
----------------------

In colonoscopy was found a rectovaginal fistula on the rectum 3 cm up from anal verge (Fig. [1](#ccr3523-fig-0001){ref-type="fig"}). An Over‐The‐Scope Clip (Fig. [2](#ccr3523-fig-0002){ref-type="fig"}) was placed successfully and the occlusion of rectovaginal leak was performed without any complications. The patient had an uncomplicated postoperative recovery.

![The colonoscopy revealed a rectovaginal fistula on the rectum 3 cm up from anal verge.](CCR3-4-449-g001){#ccr3523-fig-0001}

![Over‐the‐scope clip with its cap placed around the fistula\'s edges before vacuum‐assisted closure of fistula.](CCR3-4-449-g002){#ccr3523-fig-0002}

Despite its effectiveness in the treatment of malignant tumors, bevacizumab, as an angiogenesis inhibitor, is associated with a variety of side effects such as proteinuria, thromboembolic events, and formation of fistulas (i.e., tracheoesophageal, colovaginal, or rectovaginal) [1](#ccr3523-bib-0001){ref-type="ref"}, [2](#ccr3523-bib-0002){ref-type="ref"}, [3](#ccr3523-bib-0003){ref-type="ref"}. According to some clinical trials phase III, bevacizumab has not shown any serious interaction when combined with other chemotherapy regimen and based on AVADO trial the combination with docetaxel has no additional complications [4](#ccr3523-bib-0004){ref-type="ref"}. However, bevacizumab should be discontinued permanently if bowel fistula or perforation occurs, as happened in our case. Physicians should be aware of this entity so they can act immediately not only by stopping the drug to be prepared for a possible emergence of this side effect later.

In conclusion, herein authors believe that this article prompts the awareness that physician should have, for this relatively uncommon complication of bevacizumab usage. Furthermore, the use of Over‐The‐Scope Clip could be applied more often to other types of fistulas as a therapeutic approach. More studies should be done on producing predictive tools to recognize the patients at risk for bevacizumab‐induced bowel perforation.
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